HCC stands for hepatocellular carcinoma, the most common type of primary liver cancer. It begins in hepatocytes, the main working cells of the liver that handle everything from filtering toxins to producing bile. Unlike cancers that spread to the liver from somewhere else (which are called secondary or metastatic liver cancers), HCC originates in the liver itself. It almost always develops against a backdrop of chronic liver damage, making it one of the more preventable cancers when the underlying liver disease is caught and managed early.
How HCC Develops
The liver is one of the few organs that can regenerate after injury. That ability, ironically, is part of what makes it vulnerable to cancer. When the liver is damaged repeatedly over years, whether from a virus, alcohol, or fat buildup, it cycles through rounds of inflammation and repair. Each cycle forces liver cells to divide, and each division carries a small chance of a genetic error that pushes a cell toward uncontrolled growth.
Over time, this chronic damage produces scarring (fibrosis), which can progress to cirrhosis, a state where the liver’s architecture is so disrupted that normal function begins to fail. Cirrhosis is the single biggest risk factor for HCC. Roughly 80% to 90% of HCC cases arise in a cirrhotic liver. But cirrhosis isn’t required. Some people develop HCC before scarring reaches that stage, particularly those with fatty liver disease.
Major Risk Factors
Three broad categories of liver disease account for the vast majority of HCC cases worldwide.
Chronic hepatitis B (HBV) is the leading cause globally, especially in East Asia and sub-Saharan Africa where infection rates are highest. HBV is unusual because it can cause HCC even without cirrhosis; the virus itself can insert its DNA into liver cells and directly trigger cancerous changes.
Chronic hepatitis C (HCV) has been a major driver in Western countries and Japan. Unlike HBV, HCV almost always causes HCC through the pathway of progressive scarring and cirrhosis rather than direct genetic damage.
Non-alcoholic fatty liver disease (NAFLD) is the fastest-growing cause of HCC in the world. As HBV vaccination and antiviral cures for HCV continue to reduce virus-related cases, fatty liver disease is expected to become the leading cause of HCC in many countries. Notably, fatty liver disease accounts for a disproportionate share of HCC cases that occur without cirrhosis. In one large study, it was behind about 26% of non-cirrhotic HCC cases compared to only 13% of cases that arose in cirrhotic livers.
Heavy alcohol use is another well-established cause, and many patients have overlapping risk factors, such as heavy drinking combined with hepatitis C or obesity.
Symptoms and Detection
HCC is notoriously silent in its early stages. Most people feel nothing until the tumor is large enough to cause problems, which is why screening programs exist for people with known liver disease. Common symptoms, when they do appear, include unexplained weight loss, loss of appetite, upper abdominal pain or fullness, yellowing of the skin and eyes, and increasing abdominal swelling from fluid buildup.
For people at high risk (those with cirrhosis or chronic hepatitis B), doctors typically recommend an abdominal ultrasound every six months. A blood test measuring alpha-fetoprotein (AFP), a protein that liver tumors often release, is sometimes used alongside imaging. AFP has limitations as a standalone screening tool: at standard cutoff levels, it catches only about a quarter of early cancers, though it rarely gives a false alarm. Lowering the threshold detects more cancers but at the cost of more false positives. This is why imaging remains the backbone of surveillance.
Staging and What It Means for Prognosis
Once HCC is found, doctors assess three things simultaneously: how large and widespread the tumor is, how well the liver is still functioning, and a person’s overall physical condition. All three factors together determine what treatments are realistic. The most widely used framework, called the Barcelona Clinic Liver Cancer (BCLC) system, assigns one of five stages, from very early (stage 0) through early (A), intermediate (B), advanced (C), and end-stage (D). Each stage is linked to a recommended first-line treatment approach.
Survival statistics from the U.S. National Cancer Institute paint a clear picture of why early detection matters so much. When HCC is caught while still localized to the liver, the five-year relative survival rate is 37.4%. Once it has spread to nearby lymph nodes or tissues (regional stage), that drops to 13.4%. For cancer that has reached distant organs, the five-year survival is 3.6%.
Treatment Options by Stage
For very early and early-stage HCC, the goal is cure. That can mean surgical removal of the tumor, a liver transplant (which addresses both the cancer and the underlying cirrhosis), or ablation, a procedure that destroys the tumor using heat or extreme cold delivered through a needle. Transplant offers the best long-term outcomes for eligible patients, but the limited supply of donor organs means many people undergo resection or ablation instead.
Intermediate-stage tumors that are too numerous or too large for surgery but haven’t spread beyond the liver are often treated with procedures that target the tumor’s blood supply, delivering chemotherapy or radiation directly into the arteries feeding the cancer.
Advanced HCC, where the cancer has invaded blood vessels or spread outside the liver, is treated with systemic therapy. The current standard of care combines immunotherapy drugs that help the immune system recognize and attack cancer cells. For patients who can’t tolerate immunotherapy, targeted drugs that block the blood vessel growth tumors depend on remain an option. These treatments don’t typically cure advanced HCC, but they can extend life and slow progression significantly compared to older options.
Prevention Through Treating Liver Disease
Because HCC almost always grows out of a damaged liver, treating the underlying disease is the most effective form of prevention. The evidence here is strong and specific.
For people with chronic hepatitis B, antiviral treatment reduces the risk of developing HCC by about 63% compared to untreated patients. Even after five or more years on treatment, the annual incidence continues to drop, falling from 1.22% per year in the first five years to 0.73% per year beyond that point. For those who have already had HCC surgically removed, staying on antivirals significantly lowers the chance of the cancer coming back.
For hepatitis C, achieving a sustained viral cure (meaning the virus is permanently cleared) reduces HCC risk by 71% to 76%. The availability of oral antiviral regimens that cure hepatitis C in 8 to 12 weeks has been a major public health advance, and large-scale treatment programs are already reducing HCC rates in countries with high HCV prevalence.
For fatty liver disease, there is no single drug proven to prevent HCC, but managing the components that drive liver damage, including excess weight, insulin resistance, high blood sugar, and high cholesterol, slows or reverses the fibrosis that sets the stage for cancer. Weight loss of 7% to 10% of body weight has been shown to improve liver inflammation and scarring in people with fatty liver disease, making it one of the most impactful interventions available.
Hepatitis B vaccination, now routine in most countries, prevents infection entirely and has already begun reducing HCC rates in younger generations. In regions where universal infant vaccination was introduced decades ago, HCC incidence in young adults has measurably declined.